FDAnews Device Daily Bulletin

BAYER DIAGNOSTICS AND INVERNESS MEDICAL INNOVATIONS ANNOUNCE SERIES OF AGREEMENTS TO COMMERCIALIZE BNP AND OTHER MARKERS

Nov. 23, 2005
A A

Bayer HealthCare, Diagnostics Division, a member of the Bayer Group and Inverness Medical Innovations, a leading manufacturer and marketer of professional and consumer medical diagnostic products, recently announced that the companies have signed four agreements to broaden their assay menu offerings worldwide in the diagnostics arena. The first agreement will expand access for physicians and healthcare providers worldwide, excluding Japan, to diagnose congestive heart failure using a Point of Care assay for B-type Natriuretic Peptide (BNP) testing. Recent research has shown that elevated levels of BNP are an indicator of heart failure, thus providing physicians with an important diagnostic tool in the early detection and management of heart failure.

Yahoo News (http://biz.yahoo.com/prnews/051122/nytu065.html?.v=28&printer=1)